Key Developments: AtriCure Inc (ATRC.OQ)

ATRC.OQ on NASDAQ Stock Exchange Global Market

9.80USD
1 Aug 2013
Price Change (% chg)

$0.14 (+1.45%)
Prev Close
$9.66
Open
$9.69
Day's High
$9.90
Day's Low
$9.69
Volume
21,398
Avg. Vol
24,141
52-wk High
$10.00
52-wk Low
$5.90

Search Stocks

Latest Key Developments (Source: Significant Developments)

AtriCure Inc Raises FY 2013 Revenue Guidance; Reaffirms FY 2013 EBITDA Guidance
Thursday, 1 Aug 2013 04:03pm EDT 

AtriCure Inc announced that for fiscal 2013, it expects revenue to be in the range of $77.0 - $78.5 million, as compares to the previous outlook for fiscal 2013 revenue in the range of $76.5-$78.0 million. Adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $3.0 to $5.0 million including the impact of the medical device excise tax which is estimated to be in the range of $0.8 - $1.0 million for fiscal 2013. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $77.7 million for fiscal 2013.  Full Article

AtriCure Inc Reaffirms FY 2013 Guidance
Thursday, 2 May 2013 04:05pm EDT 

AtriCure Inc reaffirmed the previous guidance that fiscal 2013 revenue will be in the range of $76.5 - $78.0 million, adjusted EBITDA, a non-GAAP measure, is projected to be a loss in the range of $3.0 to $5.0 million including the impact of the medical device excise tax which is estimated to be in the range of $0.8 - $1.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $77.5 million and EBITDA of $(5.0) million for fiscal 2013.  Full Article

AtriCure Inc Issues FY 2013 Guidance; EBITDA Guidance Below Analysts' Estimates
Thursday, 28 Feb 2013 04:04pm EST 

AtriCure Inc announced that for fiscal 2013, it expects revenue to be in the range of $76.5 - $78.0 million and adjusted EBITDA, a non-GAAP measure, to be a loss in the range of $3.0 to $5.0 million, including the impact of the Medical Device Tax which is estimated to be in the range of $0.8 - $1.0 million. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $77.8 million and EBITDA of $(2.8) million for fiscal 2013.  Full Article

AtriCure Inc Prices Public Offering Of Common Stock
Wednesday, 16 Jan 2013 09:00am EST 

AtriCure Inc announced the pricing of its previously announced underwritten public offering of 3,475,000 shares of its common stock at a public offering price of $7.25 per share. In connection with the offering, AtriCure has also granted the underwriter a 30-day option to purchase up to an additional 521,250 shares of common stock to cover over-allotments, if any. Piper Jaffray & Co. is acting as the sole manager for the offering. Net proceeds from the sale of the shares after underwriting discounts and commissions and other offering expenses are expected to be approximately $23.5 million. The offering is subject to customary closing conditions and is expected to close on January 22, 2013. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.  Full Article

AtriCure Inc Announces Commencement Of Public Offering Of Common Stock
Tuesday, 15 Jan 2013 04:04pm EST 

AtriCure Inc announced that it intends to offer shares of its common stock in a public offering. Piper Jaffray & Co. is acting as the sole manager for the offering. AtriCure plans to use the net proceeds from the offering for general corporate purposes and working capital.  Full Article

AtriCure Inc Issues Q4, FY 2012 Revenue Guidance In Line With Analysts' Estimates
Monday, 7 Jan 2013 07:00am EST 

AtriCure Inc announced that for fourth quarter of 2012, it expects revenue to be approximately $18.4 million, reflecting growth of approximately 9.5% over the fourth quarter of 2011. For fiscal 2012, it expects revenue to be $70.2 million, reflecting year over year growth of 9.1% over full year 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $18.5 million for fourth quarter of 2012 and revenue of $70.4 million for fiscal 2012.  Full Article

AtriCure Inc Names Michael H. Carrel President and Chief Executive Officer
Thursday, 1 Nov 2012 04:10pm EDT 

AtriCure Inc announced that Michael Carrel has been appointed President and Chief Executive Officer of the Company, effective immediately.  Full Article

AtriCure, Inc. Announces Management Change-Form 8-K
Thursday, 2 Aug 2012 09:43pm EDT 

AtriCure, Inc. reported in its Form 8-K that on August 2, 2012 David J. Drachman, Chief Executive Officer (CEO) and President of the Company, notified the Company that he is resigning from his positions with the Company. Pursuant to his Employment Agreement, Mr. Drachman will continue to serve as Chief Executive Officer (CEO) and President of the Company through September 30, 2012. Mr. Drachman’s term as a member of the Company’s Board of Directors ends effective August 2, 2012. On August 2, 2012 the Company announced the formation of an Office of the Chairman led by Richard M. Johnston, Chairman of AtriCure’s Board of Directors. The Office of the Chairman will assume the responsibilities of David J. Drachman. In addition to Mr. Johnston, Michael D. Hooven shall serve as a member of AtriCure’s new Office of the Chairman.  Full Article

AtriCure, Inc. Suspends FY 2012 Guidance
Thursday, 2 Aug 2012 04:05pm EDT 

AtriCure, Inc. announced that given the recently announced management transition, the Company is suspending fiscal 2012 financial guidance until it hires a new Chief Executive Officer and that person is comfortable resuming guidance.  Full Article

AtriCure, Inc. Issues FY 2012 Revenue Guidance In Line With Analysts' Estimates
Wednesday, 2 May 2012 04:01pm EDT 

AtriCure, Inc. announced that for fiscal 2012, it expects revenue in a range of 12% to 15% growth over fiscal 2011. The Company reported revenue of $64.40 million in fiscal 2011. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $72 million for fiscal 2012.  Full Article

Search Stocks